Latest Orthopaedics News

Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.

CurveBeam AI has secured FDA 510(k) clearance for CT-based bone mineral density measurement, establishing the first regulatory step towards a potential new SaaS offering. The more commercially significant HiRise weight-bearing application still requires a separate clearance.

CurveBeam AI has secured over A$600,000 through its Share Purchase Plan, bolstering funds alongside a recent A$5 million placement. The capital will fuel the China launch and product development for its HiRise™ CT scanner.

Ramsay Health Care has finalised its $251 million purchase of National Capital Private Hospital in Canberra, expanding its footprint in key therapeutic areas and expecting earnings accretion within a year.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

CurveBeam AI’s FY2026 results show a 28% revenue decline and a 12% increase in net loss, while advancing its China commercialisation and robotic surgery integration strategies. The company also announced a $6-7 million capital raise post-year-end.

Desane Group Holdings posted a statutory net profit after tax of just $0.02 million for FY26, down sharply from $3.32 million the previous year, while advancing key property developments and maintaining a strong balance sheet.

ParagonCare’s FY26 results show modest revenue and underlying earnings growth, overshadowed by a large credit loss provision related to the Infinity Pharmacy Group debt.

Integral Diagnostics (ASX: IDX) delivered a robust FY26 with 26% revenue growth to $788.6 million, a 677% surge in profit after tax to $22 million, and a 50% hike in its final dividend to 6 cents per share.

EBOS Group posted a solid FY26, growing revenue nearly 10% to $13.5 billion and underlying EBITDA 5% to $614 million, while completing a major distribution centre renewal program. The company maintains its final dividend and sets a confident growth outlook for FY27.

Osteopore has inked a three-year distribution agreement with Al-Umnia Medical to bring its 3D-printed orthopaedic implants to five Gulf countries, targeting a rapidly expanding regional market.

CurveBeam AI has launched a Share Purchase Plan offering eligible shareholders a 10% discount on new shares, aiming to raise up to $2 million alongside a pending $5 million placement.